Receptor Protein-Tyrosine Kinases
"Receptor Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.
| Descriptor ID |
D020794
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400 D12.776.543.750.630
|
| Concept/Terms |
Receptor Protein-Tyrosine Kinases- Receptor Protein-Tyrosine Kinases
- Kinases, Receptor Protein-Tyrosine
- Protein-Tyrosine Kinases, Receptor
- Receptor Protein Tyrosine Kinases
- Receptors, Protein-Tyrosine Kinase
- Protein-Tyrosine Kinase Receptors
- Receptors, Protein Tyrosine Kinase
- PTK Receptors
- Receptors, PTK
- Tyrosine Kinase Receptors
- Protein-Tyrosine Kinase Receptor
- Receptor, Protein-Tyrosine Kinase
- Receptor Protein-Tyrosine Kinase
- Kinase, Receptor Protein-Tyrosine
- Protein-Tyrosine Kinase, Receptor
- Receptor Protein Tyrosine Kinase
- Tyrosine Kinase Linked Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptor Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Receptor Protein-Tyrosine Kinases".
- Receptor Protein-Tyrosine Kinases
- c-Mer Tyrosine Kinase
- Discoidin Domain Receptors
- ErbB Receptors
- fms-Like Tyrosine Kinase 3
- Proto-Oncogene Proteins c-kit
- Proto-Oncogene Proteins c-met
- Proto-Oncogene Proteins c-ret
- Receptor Tyrosine Kinase-like Orphan Receptors
- Receptor, Fibroblast Growth Factor, Type 1
- Receptor, Fibroblast Growth Factor, Type 2
- Receptor, Fibroblast Growth Factor, Type 3
- Receptor, Fibroblast Growth Factor, Type 4
- Receptor, IGF Type 1
- Receptor, Insulin
- Receptor, Macrophage Colony-Stimulating Factor
- Receptor, trkA
- Receptor, trkB
- Receptor, trkC
- Receptors, Eph Family
- Receptors, Platelet-Derived Growth Factor
- Receptors, TIE
- Receptors, Vascular Endothelial Growth Factor
This graph shows the total number of publications written about "Receptor Protein-Tyrosine Kinases" by people in this website by year, and whether "Receptor Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 2 | 3 |
| 1995 | 4 | 0 | 4 |
| 1996 | 2 | 2 | 4 |
| 1997 | 3 | 0 | 3 |
| 1998 | 0 | 3 | 3 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 2 | 3 |
| 2004 | 4 | 2 | 6 |
| 2005 | 2 | 3 | 5 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 1 | 3 |
| 2010 | 2 | 2 | 4 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 3 | 4 |
| 2013 | 2 | 2 | 4 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor Protein-Tyrosine Kinases" by people in Profiles.
-
Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. PLoS One. 2021; 16(7):e0241766.
-
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle Nerve. 2019 04; 59(4):404-410.
-
Indeed, Nuance Matters. J Thorac Oncol. 2019 01; 14(1):e16-e17.
-
"Teachable Moment" Interventions in Lung Cancer: Why Action Matters. J Thorac Oncol. 2018 05; 13(5):603-605.
-
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology. 2017 Sep 05; 89(10):1069-1077.
-
Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. Oncotarget. 2016 Jun 14; 7(24):36138-36153.
-
May the fibrosis be with you: Is discoidin domain receptor 2 the receptor we have been looking for? J Mol Cell Cardiol. 2016 Feb; 91:201-3.
-
The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer. Ther Adv Respir Dis. 2015 Oct; 9(5):236-41.
-
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015 Feb; 10(2):232-6.
-
Neurotropin promotes NGF signaling through interaction of GM1 ganglioside with Trk neurotrophin receptor in PC12 cells. Brain Res. 2015 Jan 30; 1596:13-21.